Quick Summary
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals Fertilizers, Department of Pharmaceuticals, has issued an Office Memorandum (F. No. 12(24)/2021/1DP/NFPA/Div.II(Vol.II)-Part(1)) mandating the implementation of revised Maximum Retail Prices (MRPs) for medicines,
Daily Limit Reached
You have reached your daily limit of 2 Free News
Subscribe to CCI PRO for unlimited access
Why Upgrade to CCI PRO?
- No Ads
- WhatsApp Broadcasts
- Daily E-Newsletter
- Unlimited News Access
BEST VALUE
2 YEAR PLAN
3,499
(Inclusive of GST)
1 YEAR PLAN
1,999
(Inclusive of GST)
Buy CCI PRO Now
Already a PRO member? Login here for an ad-free experience.
FAQ :
The NPPA has directed drug manufacturers and marketing companies to pass on the benefits of reduced GST rates to consumers by revising the Maximum Retail Prices (MRPs) of medicines and medical devices.
The revised MRPs, reflecting the reduced GST rates, will be effective from 22nd September 2025.
No, it is not mandatory to re-label or re-sticker products already in the market before 22nd September 2025, provided the revised MRPs are publicly communicated.
Manufacturers are directed to use all communication channels, including print, electronic, and social media, to inform dealers, retailers, and consumers about the revised GST rates and MRPs.
Industry associations are encouraged to release advertisements in leading national and vernacular newspapers to inform dealers and retailers about the revised GST rates and ensure compliance.
Yes, manufacturers can opt for phased re-labelling or re-stickering of stock, provided it does not lead to shortages of drugs or medical devices.
CAclubindia
